Galaxy Surfactants, Alkem Labs, KNR Construction, Medplus, Ashoka Buildcon & More Q2 Review: HDFC Securities

The brokerage maintains 'Buy' rating on Galaxy Surfactants and HG Infra, Here's Why

   (Photo source: StockSnap/Pixabay)

NDTV Profit’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer NDTV Profit’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.

HDFC Securities Institutional Equities

Galaxy Surfactants - Premium Speciality to drive growth

Our BUY recommendation on Galaxy Surfactants Ltd. with a price target of Rs 3,466 is premised on-

  1. the global home and personal care leaders having raised the volume growth outlook for 2024 after strong volumes in YTD;

  2. demand for premium specialty care products expected to rebound as demand in Europe and North America rebounds with the easing of inflation and the end of inventory destocking; and

  3. demand in RoW markets continuing.

Q2 Ebitda/adjusted profit after tax were 30/38% above our estimates owing to higher-than-expected revenue and offset by higher-than-expected raw material cost.

HG Infra - Weak Performance

HG Infra Engineering Ltd. reported its quarterly revenue/Ebitda/APAT of Rs 10.6 billion/1.7 billion/886 million, a miss by 21/17.5/17.4%. The order book as of Sep’24 stood at Rs 166.2 billion (~3.2x FY24 revenue). The company has maintained its FY25 revenue guidance at Rs 60 billion (~17% YoY) with an Ebitda margin of ~15-16%.

On the order inflow front, the company expects Rs 110-120 billion. It has already secured orders worth Rs 62.8 billion (Rs 55 billion from highways and Rs 7.8 billion from Solar) and is on track to achieve FY25 guidance.

HG recently made a pivotal shift in its order book inflows from road to railways indicating its robust diversification strategy, and it further expects to diversify in the water segment by securing new orders.

Equity infusion guidance for H2 FY25/26/27 stands at Rs 3.7/ 1.7/ 1.31 billion. The standalone gross/net debt as of Sep-24 stood at Rs 8.8/7.7 billion versus Rs 6.2/5.1 billion, as of June-24. Given robust order book, likely pick-up in project execution and a healthy balance sheet, we maintain Buy on HG, with target price of Rs 1,904 (16 times 1- yr forward).

Click on the attachment to read the full report:

HDFC Securities Institutional Equities - Alkem Labs, Galaxy Surfactants, HG Infra, KNR Construction, Medplus, Ashoka Buildcon, Neogen, Kolte-Patil Q2FY25 Results Review.pdf
Read Document

Also Read: Alkem Labs Q2 Results Review - U.S. Drags Earnings: Motilal Oswal

DISCLAIMER

This report is authored by an external party. NDTV Profit does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of NDTV Profit.

Users have no license to copy, modify, or distribute the content without permission of the Original Owner.

lock-gif
To continue reading this story
Subscribe to Unlock & Enjoy your
Subscriber-Only benefits
Still Not convinced ?  Know More
Watch LIVE TV , Get Stock Market Updates, Top Business , IPO and Latest News on NDTV Profit.
GET REGULAR UPDATES